Charles G. Bailey

TL;DR: The molecular sequelae of PS-341 treatment in MM cells are characterized and the rationale for future clinical trials of this promising agent, in combination with conventional and novel therapies, to improve patient outcome in MM is explained.

TL;DR: This study found that subtoxic concentrations of PS-341 potently sensitized MM cell lines and patient cells to DNA-damaging chemotherapeutic agents such as doxorubicin and melphalan, including cells resistant to these drugs and those isolated from a patient who had relapsed afterPS-341 monotherapy.

TL;DR: It is found that MM cells are irreversibly committed to cell death within few hours of incubation with SAHA, which highlights the pleiotropic antitumor effects of HDAC inhibition, and provides the framework for future clinical applications of SAHA to improve patient outcome in MM.

TL;DR: Bioinformatic analyses of transcriptomic and proteomic data of normal white blood cell differentiation reveal IR as a physiological mechanism of gene expression control and establish that IR coupled with NMD is a conserved mechanism in normal granulopoiesis.

TL;DR: Preclinical evidence for the feasibility of novel therapies exploiting ASCT2 transporter activity in breast cancer is provided, particularly in the high-risk basal-like subgroup of TN breast cancer where there is not only high expression of AsCT2, but also a marked reliance on its activity for sustained cellular proliferation.